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Introduction
Primary myelofibrosis (PMF) is a Philadelphia chromo-
some-negative myeloproliferative neoplasm characterized by
clonal myeloproliferation, dysmegakaryopoiesis and
extramedullary hematopoiesis associated with myelofibrosis
and altered bone marrow (BM)/splenic stroma.1 The myelo-
proliferative process features an increased number of CD34+
hematopoietic stem/progenitor cells with hypersensitivity to
cytokines, which have been attributed to the presence of
mutations including Jak2V617F and MPL515L/K.2,3 More recently,
various other mutations affecting epigenetics,4,5 the spliceo-
some6 and metabolism7 have been discovered and have been
correlated with a worse prognosis8 and with leukemic trans-
formation.4 The myeloproliferation is associated with mas-
sive mobilization of CD34+ hematopoietic stem/progenitor
cells, including megakaryocyte progenitors, from the BM to
the spleen, which was suggested to be partly due to down-
regulation of the expression of CXCR4, one of the two
CXCL12 receptors.9 PMF megakaryocytes are characterized
by prominent proliferation, a dysplastic appearance with a
plump nucleus and altered nuclear/cytoplasmic maturation.
They also have changes in the process of apoptosis depending
on the stromal context. Indeed, a para-apoptotic process was
observed in BM biopsies,10 contrasting with data from molec-
ular studies11 and CD34+ hematopoietic stem/progenitor cell
cultures,12 which showed a reduction of the apoptotic
process. Furthermore, evidence is accumulating that altered
stromal cells in the BM and spleen of PMF patients may con-
tribute to the hematopoietic clone emergence/development
through mutually dependent interactions with clonal
hematopoietic cells.1
CD9, a four transmembrane glycoprotein that belongs to
the tetraspanin family,13 has recently been reported to be
deregulated in PMF. It is strongly expressed on platelets14 and
was first cloned from megakaryocyte libraries.15 Treatment of
K562 cells with tetradecanoylphorbol-13-acetate induces
megakaryocytic differentiation associated with up-regulation
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Primary myelofibrosis is characterized by clonal myeloproliferation, dysmegakaryopoiesis, extramedullary
hematopoiesis associated with myelofibrosis and altered stroma in the bone marrow and spleen. The expression
of CD9, a tetraspanin known to participate in megakaryopoiesis, platelet formation, cell migration and interaction
with stroma, is deregulated in patients with primary myelofibrosis and is correlated with stage of myelofibrosis.
We investigated whether CD9 participates in the dysmegakaryopoiesis observed in patients and whether it is
involved in the altered interplay between megakaryocytes and stromal cells. We found that CD9 expression was
modulated during megakaryocyte differentiation in primary myelofibrosis and that cell surface CD9 engagement
by antibody ligation improved the dysmegakaryopoiesis by restoring the balance of MAPK and PI3K signaling.
When co-cultured on bone marrow mesenchymal stromal cells from patients, megakaryocytes from patients with
primary myelofibrosis displayed modified behaviors in terms of adhesion, cell survival and proliferation as com-
pared to megakaryocytes from healthy donors. These modifications were reversed after antibody ligation of cell
surface CD9, suggesting the participation of CD9 in the abnormal interplay between primary myelofibrosis
megakaryocytes and stroma. Furthermore, silencing of CD9 reduced CXCL12 and CXCR4 expression in primary
myelofibrosis megakaryocytes as well as their CXCL12-dependent migration. Collectively, our results indicate
that CD9 plays a role in the dysmegakaryopoiesis that occurs in primary myelofibrosis and affects interactions
between megakaryocytes and bone marrow stromal cells. These results strengthen the “bad seed in bad soil”
hypothesis that we have previously proposed, in which alterations of reciprocal interactions between hematopoi-
etic and stromal cells participate in the pathogenesis of primary myelofibrosis.
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ABSTRACT
of CD9 expression which precedes the appearance of
GPIIb/IIIa.16 We have previously demonstrated that CD9
participates in normal megakaryopoiesis and platelet for-
mation through its action on megakaryocyte demarcation
membrane separation.17 In PMF patients, CD9 molecular
expression is increased in CD34+ cells,18 as well as in
megakaryocytes microdissected from BM biopsies, and is
reported to be correlated with the stage of BM fibrosis.19
Beside its role in megakaryopoiesis, CD9 is suggested to
regulate interactions with the microenvironment by pro-
moting the recruitment of numerous molecular partners
grouped in lipid-rich microdomains, including integrins
that are receptors for extracellular matrix components
such as collagen, laminin and fibronectin.13 CD9 also par-
ticipates in cell adhesion/motility20 and, in CD34+ cells, the
CD9-mediated mobilization involves the CXCL12/
CXCR4 axis.21
Taking into account the role of CD9 in megakary-
opoiesis and in BM stromal interactions, we analyzed the
role of CD9 in the pathogenesis of PMF. Herein, we show
that CD9 takes part in the alterations affecting the sur-
vival, differentiation and CXCL12/CXCR4-mediated
migration of PMF megakaryocytes. We also demonstrate
that CD9 is involved in the altered interactions between
megakaryocytes and BM mesenchymal stromal cells
(MSC) isolated from patients, participating in the dys-
megakaryopoiesis of PMF. 
Methods
Peripheral blood and bone marrow samples 
Peripheral blood and BM samples from PMF patients (n=174)
and non-mobilized healthy donors (HD; n=76) were obtained
from the French/European networks, A.M. Vannucchi (Florence,
Italy), and the Blood Transfusion Center of Armies (Clamart,
France) according to the Helsinki declaration and with approval
from Institutional Ethics Committees.
CD34+ cell selection and bone marrow mesenchymal
stromal cells 
CD34+ cells were selected from mononuclear cells from periph-
eral blood or BM samples from PMF patients and HD using the
Miltenyi miniMACS system.22
BM MSC were obtained from BM biopsies (PMF patients) or
hip surgery (HD) by incubating BM mononuclear cells (5x106/mL)
for 48-72 h in plastic flasks. Adherent MSC were cultured in
DMEM + 10% SVF in 5% CO2 for three passages. 
Phenotypic analysis 
Cells (5x104) were labeled with 2 μg/mL monoclonal antibodies:
CD105-PE/clone-166707, CD9-FITC/clone-209306, HLA-DR-
FITC/clone-L203 (R&D systems); CD73-PE/clone-AD2, CD62P-
PE/clone-AC1.2, CD90-PE/clone-5E10, CXCR4-PE/clone-12G5
(BD Biosciences); CD41-FITC/CD41-PE (clone-P2, IOTest
Beckman-Coulter); and CD9-biotinyled/clone-SYB (a kind gift
from E. Rubinstein and C. Boucheix). Membrane antigen fluores-
cence was quantified using Cellquest software on a FACScalibur
(Becton-Dickinson); 5x103 live cells were analyzed. 
Megakaryocytes derived from CD34+ cultures
CD34+ cells (5x104/500 μL/well) were cultured in SYN.H medi-
um containing recombinant human (rh) interleukin (IL)-3 (2
ng/mL), rhIL-6 (1 ng/mL), rhIL-11 (40 ng/mL), and rh thrombopoi-
etin (Tpo) (50 ng/mL) (Preprotec, France) giving rise to more than
85% of megakaryocytes after 10 to 14 days of culture. In some
experiments, cultures were treated with monoclonal antibodies
(anti-CD9/clone-SYB: 10 μg/mL). For RNA silencing, cells were
cultured for 6 days and distributed in 250 μL 24-well plates with
or without scrambled control or specific short interfering (si) RNA
(1 μg/106 cells) and MISSION II vector (1/50; Sigma). 
Colony-forming units-megakaryocyte 
Circulating CD34+ cells (5x103) were seeded in Megacult C con-
taining type-I bovine collagen (Stem Cell), rhIL-3 (1 µg/mL), rhIL-
6 (10 μg/mL), and rhTpo (10 μg/mL). Colony-forming units-
megakaryocyte (CFU-Mk) were quantified, on the basis of CD41
immunostaining, after 10 days of culture at 37°C in 5% CO2. 
Analysis of intracellular phosphorylation 
Cells were fixed for 1 h in formol-2% and overnight in ethanol-
70% (4°C). After washes in PBS-0.5%+BSA-Triton-0.25X, cells
were incubated with phosphorylated protein monoclonal antibod-
ies (Cell Signaling, USA), washed and incubated with a secondary
anti-rabbit Alexa-fluor-488nm coupled antibody (Invitrogen,
France). Live cells (104) were analyzed on FACScalibur with
Cellquest software.
Western blotting 
Cell lysates (105 cells), obtained as described previously,22 were
subjected to sodium dodecylsulfate polyacrylamide gel elec-
trophoresis, transferred onto nitrocellulose membranes and blot-
ted using primary monoclonal antibodies (Cell Signaling, USA).
Membranes were revealed with fluorescent anti-mouse or anti-
rabbit IgG. Fluorescence signals were detected on an Odyssey
System (Li-cor, USA) and quantified by using ImageJ version
1.43u.
In vitro migration assay 
Transwell migration assays were performed as described else-
where.22 Cells (105) were loaded on the top chamber in RPMI/0.5%
BSA and CXCL12 (100 ng/mL, R&D System) was added or not to
the bottom chamber. Cells were incubated for 24 h or 48 h (siRNA
treatment); the migration percentage was calculated after quantifi-
cation of live cells in both chambers.
Quantitative real-time polymerase chain reaction analysis 
Samples of total RNA were treated with RNase-free-DNase and
converted into cDNA using the Reverse-Transcription kit
(Applied-Biosystem). cDNA (2 μL) was added to a Quantitech
SybrGreen amplification reaction (Qiagen, Courtaboeuf, France)
in a final volume of 20 μL containing 10 pmol of each primer
(Online Supplementary Table S1). Relative quantification was nor-
malized to RPL38 using the 2ΔΔCT method.23
Statistical analysis 
Results are expressed as mean ± standard deviation. Statistical
differences between patients and controls or between conditions
were validated by unpaired or paired t-tests, respectively, with
P<0.05 being considered statistically significant. Paired data are
represented in dot plots with lines between significant conditions.
Results
CD9 expression is deregulated during 
megakaryopoiesis in primary myelofibrosis
CD9 is reported to participate in megakaryopoiesis and
in platelet formation. We therefore evaluated whether its
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expression was modulated during PMF megakaryopoiesis.    
As previously described,18,19 Figure 1A illustrates that CD9
mRNA was increased 2.54-fold in PMF circulating CD34+
cells compared to CD34+ cells from unmobilized HD
[(1.531±0.7413 arbitrary units (AU), n=12 versus
0.6019±0.0928 AU, n=7, respectively; P=0.0023].
Surprisingly, when quantified by flow-cytometry, the level of
expression of CD9 on the membrane of circulating CD34+
cells from patients was heterogeneous compared to that on
circulating CD34+ or CD42b-CD34+ cells from non-mobilized
HD controls (259.5±58.54 AU, n=14 and 218.5±47.02 AU,
n=10, respectively; Figure 1B). Heterogeneity in the CD9
expression on CD34+ cells between patients was ranked, dis-
criminating three groups according to the level of CD9
expression (544.8±195.5 AU, n=9; 234.9±44.38 AU, n=14
and 97.09±33.18 AU, n=23) (Figure 1B). Figure 1C shows that
most of the patients with a low number of platelets had low
expression of CD9 on CD34+ cells. When quantified on
platelets, the global CD9 membrane expression level was sig-
nificantly lower in patients than in HD (116.1±150.4 AU, n=3
versus 406.4±83.73 AU, n=4, respectively; P=0.01; Figure 1D). 
We further analyzed CD9 expression during in vitro
megakaryocyte differentiation. At the end of in vitro
megakaryocyte differentiation on day (D) 10, a lower propor-
PMF CD9-mediated megakaryocyte-stroma interactions
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Figure 1. CD9 expression is deregu-
lated during PMF dysmegakary-
opoiesis. (A) Expression of CD9
transcripts normalized to RPL38 by
QRT-PCR in CD34+ cells from
healthy donors (HD) and primary
myelofibrosis (PMF) patients. (B)
CD9 membrane expression (MFI)
by flow cytometry on CD34+ cells
purified from the peripheral blood
(PB) of HD and PMF patients and
CD9 membrane expression rank-
ing (gray bars: PMF patients; white
bars: HD). (C) Correlation between
the CD9 membrane expression
level on PMF CD34+ cells and the
patient’s platelet count. (D) CD9
expression level on HD and PMF
circulating platelets determined by
flow cytometry (MFI). (E) Co-expres-
sion of CD9 and CD41 on PMF
megakaryocytes derived from HD
and PMF circulating CD34+ cells
(D10 of culture). (F) Membrane
expression analysis of CD9 on
megakaryocytes (Mks) derived
from CD34+ cells purified from the
bone marrow (BM) or PB of HD and
PMF patients (D10 of culture) by
flow cytometry. (G) Western blot
analysis and quantification of CD9
expression in Mks derived from cir-
culating CD34+ cells from HD and
PMF patients (D10 of culture).
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tion of megakaryocytes derived from PMF circulating CD34+
cells co-expressed CD9 and CD41 compared to the propor-
tion from HD with a different expression profile (Figure 1E).
The higher proportion of CD9+ cells that did not co-express
CD41 in PMF patients is most likely mainly due to
megakaryocyte progenitors (Online Supplementary Figure S1).
Actually, CD9 expression on megakaryocytes derived
from PMF CD34+ cells was significantly reduced
(988.2±788.2 AU, n=11) as compared to the expression on
those derived from HD cells, independently of whether
these cells were isolated from BM (2322±617 AU, n=6) or
peripheral blood (1628±252.68.3 AU, n=11) (versus HD
BM: P=0.0014 and versus HD peripheral blood: P=0.0092)
(Figure 1F). The reduction of CD9 protein expression on
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Figure 2. CD9 is involved
in PMF dysmegakary-
opoiesis. Effect of mono-
clonal antibody (mAb)
ligation of surface CD9
(clone-SYB; 10 μg/mL)
on (A) PMF megakary-
ocyte (Mk) colonies
obtained from PMF cir-
culating CD34+ cells in
semi-solid collagen cul-
ture and (B) in liquid cul-
tures (D8-10 of culture)
on cell maturation
(Giemsa) as well as
CD41 and CD62p mem-
brane expression (MFI)
determined by flow
cytometry, (C) on per-
centage of apoptotic
annexin V+ cells and Bcl-
XL expression level (MFI)
determined by flow
cytometry, (cells were
gated on megakaryocyt-
ic cells derived from PMF
CD34+ cell culture in the
presence of a cocktail of
cytokines including IL3,
IL6, IL11 and TPO; a red
quadrant corresponding
to the addition of annex-
in V+ and pre-aptototic
propidium-iodide– (IP)
cells and of annexin V+
and post-apoptotic IP+
cells was drawn to define
the total proportion of
apoptotic cells), (D) on
GATA-1 expression as
shown by QRT-PCR and
western blot analyses
and by immunofluores-
cence microscopy and
(E) on modulation of c-
myb expression by QRT-
PCR analysis.
A B
C
D
E
PMF megakaryocytes was further confirmed by western
blot analysis (HD: 73.73±0.51 versus PMF: 28.54±10.50;
P=0.01) (Figure 1G). Taken together, our results show
deregulation of CD9 expression during PMF megakary-
opoiesis. 
CD9 participates in dysmegakaryopoiesis 
in primary myelofibrosis
The differential CD9 expression during megakary-
opoiesis incited us to investigate the potential role of CD9
in the dysmegakaryopoiesis that characterizes PMF.
Figure 2A shows that cell surface CD9 engagement by
antibody ligation (Syb clone, 10 μg/mL) during in vitro
megakaryocyte differentiation from PMF CD34+ cells
stimulated megakaryocyte differentiation, as evidenced
by an increased number of CFU-Mk (189.3±108.7, n=8
versus 99.63±63.91 for anti-CD9-treated cells and IgG-
treated control cells, respectively, for 5,000 CD34+ seeded
cells; P=0.002) at D10 of culture. This was associated with
an increase in CFU-Mk size and with the presence of large
megakaryocytes in colonies. A similar effect of Syb mono -
clonal antibody was observed in liquid culture, with the
PMF CD9-mediated megakaryocyte-stroma interactions
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Figure 3. CD9 controls
Akt/MAPK balance during PMF
dysmegakaryopoiesis. Analysis
by cytometry, microscopy and
western blot of (A) phospho-
Akt (Thr308 and Ser473), -
GSK3β (Ser9) levels (MFI), or
(B) phospho-p38 (Thr180 and
Tyr182) and phospho-JNK lev-
els (MFI) in megakaryocytes
(Mk) derived from PMF circulat-
ing CD34+ cells (D6 of culture
in the presence of Tpo) at 2,
24, and 48 h after anti-CD9
monoclonal antibody (mAb)
(clone-SYB; 10 μg/mL) treat-
ment. (A and B) Data were nor-
malized either to IgG control
values or to total protein level.
(B) QRT-PCR analysis of AP1
transcript expression level in
Mk derived from PMF circulat-
ing CD34+ cells, treated or not
with anti-CD9 mAb (clone-SYB;
10 μg/mL) and normalized to
actin level.
BA
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presence of mature megakaryocytes with multi-lobulated
nuclei and large granular cytoplasm in Syb-treated cul-
tures, contrasting with dysplastic immature
micromegakaryocytes with hypolobulated nuclei
observed in untreated PMF cells. This differentiating effect
was also associated with increased expression of
megakaryocyte differentiation markers such as CD41
(1030±308.8 AU for anti-CD9-treated cells versus
769.5±228.3 AU for IgG-treated control cells, n=4, P=0.01)
and CD62p (91.75±24.02 AU for anti-CD9-treated cells
versus 60.0±11.34 AU for IgG-treated control cells, n=4,
P=0.04) (Figure 2B). 
Antibody ligation of CD9 on megakaryocytes derived
from PMF CD34+ cells also increased the percentage of
PMF annexin-V+ apoptotic cells associated with megakary-
ocyte maturation and reduced the level of anti-apoptotic
Bcl-xL expression compared to those of IgG-treated con-
trol cells (15.92±11.51%. versus 23.45±8.81%, n=5, P=0.02
and 45.48±29.10 AU versus 16.8±16.95 AU, n=5, P=0.03,
respectively) (Figure 2C).
We further studied the effect of cell surface CD9
engagement by antibody ligation on GATA-1 and c-Myb
(two transcriptional regulators whose expression has
opposing effects on megakaryocyte differentiation) during
in vitro megakaryocyte differentiation of PMF CD34+ cells
(D8-D10). Figure 2D shows that the molecular and protein
expression of GATA-1, reported to be down-regulated in
PMF megakaryocytes,24 was increased after anti-CD9
monoclonal antibody treatment compared to that of IgG-
treated control cells (1.153±0.5487 versus 0.5744±0.2921,
P=0.04, n=5, respectively in quantitative real-time poly-
merase chain reaction (QRT-PCR) experiments and 0.77
versus 0.55 for the Gata-1/Actin ratio in western blot
analysis). The increase in GATA-1 protein expression after
CD9 ligation was also confirmed by immunocytochem-
istry (Figure 2D). In contrast, the expression of c-Myb was
8.32-fold higher in PMF megakaryocytes than in HD
megakaryocytes (37.26±66.44 versus 4.47±3.89, n=6;
P=0.03) and its over-expression was reduced after CD9
antibody ligation (15.53±4.40 versus 10.5±4.82, n=4,
P=0.007) in all tested patients (Figure 2E).
Altogether our results show that targeting CD9 through
cell surface ligation with Syb monoclonal antibody
restores the in vitro maturation of PMF megakaryocytes
and suggest that CD9 participates in the dysmegakary-
opoieis observed in patients with PMF. 
CD9 controls Akt/MAPK balance during 
dysmegakaryopoiesis in primary myelofibrosis
A balance between Akt (Akt, GSK3β) and MAPK (JNK,
p38, p42/p44) signaling pathways is reported to be critical
for megakaryopoiesis. We, therefore, studied whether cell
surface CD9 engagement by antibody ligation (Syb clone,
10 μg/mL) modified the Akt/MAPK balance in megakary-
ocytes derived from PMF CD34+ cultures (D6-8) in the
presence of Tpo. 
Figure 3A shows that cell surface CD9 engagement by
antibody ligation reduced the phosphorylation level of
Akt in PMF megakaryocytes, as evaluated by flow cytom-
etry [mean fluorescence intensity (MFI) normalized to
IgG-treated control cells over time: -11.93±7.215 AU,
P=0.02; -7.865±3.524 AU, P=0.007; -3.495±1.724 AU,
P=0.007, n=4] and western blot analysis (phospho-Akt
Thr308 and Ser473 normalized to total Akt: 0.28 versus
0.80 for anti-CD9 monoclonal antibody-treated cells versus
IgG-treated control cells). It also slightly decreased PTEN
expression normalized to actin expression (0.51 versus 0.64
for anti-CD9 monoclonal antibody-treated cells versus
IgG-treated control cells; data not shown) and decreased the
phosphorylation level of downstream GSK3β on serine 9
in PMF megakaryocytes (phospho-GSK3β Ser9 normal-
ized to total GSK3β: 0.31 versus 0.56 for anti-CD9 mono-
clonal antibody-treated cells versus IgG-treated control
cells). In contrast, as shown by flow cytometry, a similar
concentration of anti-CD9 monoclonal antibody induced
an increase phosphorylation of: (i) JNK (MFI normalized to
IgG-treated control cells over time: 12.01±8.48 AU,
P=0.04; 15.21±9.82 AU, P=0.03; 25.59±18.68 AU, P=0.04;
n=4), and (ii) p38 MAPK (MFI normalized to IgG-treated
control cells over time: 3.563±1.449 AU, P=0.02;
11.12±7.55 AU, P=0.04; 14.39±10.78 AU, P=0.04; n=4)
(Figure 3B). This increased phosphorylation was con-
firmed by immunocytology and by western blot analysis
of PMF megakaryocytes (phospho-p38α Thr180 and
Tyr182 normalized on total p38α: 0.64 versus 0.41 anti-
CD9 monoclonal antibody-treated cells versus IgG-treated
control cells). We also observed a 2-fold increase in the
expression of Jun/AP1, a transcription factor downstream
of p38 and JNK, as shown by QRT-PCR (0.064 ± 0.057 ver-
sus 0.031±0.339; P=0.02, n=7, fold change = +2.03) (Figure
3B); phosphorylation of ser73 Jun normalized to total Jun
was also found to be increased (0.81 versus 0.52, Figure
3B). In contrast, a similar anti-CD9 treatment did not mod-
ulate the level of phosphorylation of MAPK p42/p44 (data
not shown). Collectively, our results show that CD9 con-
trols the balance of the Akt/MAPK signaling pathways
during PMF dysmegakaryopoiesis.
CD9 mediates megakaryocyte-mesenchymal stromal
cell interactions in primary myelofibrosis 
Taking into account the role of MSC in megakaryocyte
proliferation and migration,25 we further studied whether
CD9 influenced interactions between megakaryocytes
and BM MSC and consequently played a role in
megakaryocyte deregulation. 
Tetraspanin CD9 has been shown to interact with stro-
mal cells through cell surface molecules including CD44,
immunoglobulin-like domain containing receptors and
integrins within the teraspanin web, named the interac-
tome (“Human Protein Reference Database” and
“BioGRID 3.1” interactions on the website of the National
Institute of Health).13,26,27 We, therefore, first studied
whether the CD9 interactome genes involved in
hematopoietic cell and MSC interactions were deregulat-
ed in patients. To that purpose, we isolated MSC from the
BM of PMF patients (PMF-MSC) and HD (HD-MSC) and
verified that cells from both origins expressed the canoni-
cal CD73+CD105+CD90+ phenotypic profile of MSC and
that they did not express CD45, CD34 hematopoietic
markers or HLA-DR (Online Supplementary Figure S2).
Then, based on a gene set established on the NCBI data-
base CD9 interactome (Online Supplementary Table S2), we
applied gene set enrichment analysis to compare transcrip-
tomes between BM PMF-MSC and HD-MSC (GEO sub-
mission number GSE44426), and evidenced a deregulation
of CD9 interactome genes in PMF-MSC compared to HD-
MSC (Online Supplementary Table S2 and Online
Supplementary Figure S3). This deregulation was associated
with a down-regulation of CD9 expression on PMF-MSC
as compared to HD-MSC, both at transcriptional level
PMF CD9-mediated megakaryocyte-stroma interactions
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Figure 4. CD9 mediates PMF megakaryocyte-mesenchymal stromal cell interactions. (A) Analysis of CD9 transcript (QRT-PCR) and membrane
expression (flow cytometry) levels in MSC isolated from the bone marrow of PMF patients (BM-MSC). (B) Effect of 2 days of co-culture between
PMF megakaryocytes (Mk) derived from CD34+ culture (at D6 of Mk culture) and BM-MSC on the number of PMF Mk in suspension. (C) Effect
of surface CD9 ligation by anti-CD9 monoclonal antibody (mAb ) (clone-SYB; 10 μg/mL) on the proportion of PMF Mk derived from CD34+ cul-
ture in apoptosis (annexin V+ cells) and in the cell cycle phases (S+G2M cells) as well as on the cell count of non-adherent PMF Mk in the co-
culture with BM MSC. (D) Effect of surface CD9 ligation by anti-CD9 mAb on the proportion of adherent PMF CD45+ hematopoietic cells
obtained after co-culture on BM MSC isolated from HD or PMF patients and on adherent PMF Mk in co-culture with MSC isolated from the BM
of either HD or PMF patients as shown by Giemsa staining and immunostaining (CD41+ Mk, in pink and CD105+ MSC, in orange).
B
C
A
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(QRT-PCR normalized to the RPL38 housekeeping gene:
14.36±6.028, n=11 versus 21.87±12.56, n=9 for PMF
patients and HD, respectively; P=0.05) and protein level
(MFI by flow cytometry: 7.38±0.76 AU, n=3 versus
13.07±2.63 AU, n=4 for PMF patients and HD, respective-
ly; P=0.008) (Figure 4A).
Subsequently, we compared the effects of PMF-MSC
and HD-MSC on the survival and proliferation of
megakaryocyte progenitors derived from PMF CD34+ cells
in megakaryocyte culture medium (at D6) and analyzed
the effect of CD9 membrane ligation by Syb on these
processes (from D6 to D8-D10). Figure 4B shows that the
number of non-adherent PMF megakaryocytes was higher
when PMF hematopoietic cells were co-cultured on PMF-
MSC rather than on HD-MSC (from 100,000 implanted
hematopoietic cells/mL to 232,600±68,197/mL and
149,800±52,060/mL at D6 of co-culture, respectively; n=5,
P=0.03) (Figure 4B). 
The higher number of non-adherent PMF megakaryo -
cytes recovered after co-culture on PMF-MSC resulted
from: (i) a lower percentage of annexin V+ apoptotic cells
(17.68±2.79%, n=5 versus 25.65±6.47%; n=5; P=0.01)
(Figure 4C); and (ii) a higher percentage of Ki67+IP+ cycling
(S+G2M) cells (63.27±16.62%, n=5 versus 55.23±16.97%
n=5, P=0.002) (Figure 4C) which was associated with the
presence of PMF CD41+ megakaryocytes in mitosis (Figure
4D). CD9 ligation using Syb monoclonal antibody reduced
the number of PMF megakaryocytes in suspension in all
tested patients (232,600±68,197 versus 155,600±26,604,
n=5; P=0.04; Figure 4C), demonstrating the participation
of CD9 in this process. As expected, this was associated
with an increased percentage of apoptotic cells
(29.38±7.55% versus 17.68±2.79%, n=5; P=0.006) and a
reduced proportion of Ki67+IP+ cycling (S+G2M) cells
(49.01±19.01% versus 62.27±16.62%, n=5; P=0.003)
(Figure 4C). 
The higher number of PMF megakaryocytes in suspen-
sion is also compatible with their differential adhesion to
PMF-MSC or HD-MSC. Cytometric analysis showed that,
after trypsin treatment, a lower fraction of CD45+
hematopoietic cells was recovered in the adherent phase
of co-cultures with MSC from patients than MSC from
HD, suggesting that PMF megakaryocytes were less adhe-
sive to PMF-MSC than to HD-MSC (Figure 4D). Here
again, the altered adhesion of megakaryocytes to PMF-
MSC was inhibited after CD9 ligation with Syb mono-
clonal antibody (Figure 4D), confirming the involvement
of CD9 in the deregulated in vitro megakaryocyte-MSC
interactions in PMF.
CD9 mediates megakaryocyte migration in response 
to CXCL12 in primary myelofibrosis 
The CD9-mediated altered PMF megakaryocyte adhe-
sion to stroma incited us to study the involvement of CD9
in the increased megakaryocyte mobilization/migration
observed in the peripheral blood of patients with PMF.
Phenotypic analysis performed on megakaryocyte cul-
tures at D10 showed that all CD41 megakaryocytes from
PMF patients co-expressed CXCR4 (Figure 5A). Actually,
like megakaryocyte CD41+ cells from HD BM, megakary-
ocytes from PMF patients conserved a high level expres-
sion of CXCR4 receptor responsible for CXCL12-induced
migration. Figure 5B shows that the percentage of cells co-
expressing CD9 and CXCR4 was higher in the CD41high
population than in the CD41low one, suggesting an
increased co-expression of CD9 and CXCR4 during PMF
megakaryocyte differentiation. Interestingly, cell surface
CD9 engagement by Syb antibody ligation reduced the
mRNA expression of both CXCR4 (0.028±0.015, n=4 ver-
sus 0.048±0.16, n=4; P=0.04) and CXCL12
(0.0044±0.0026, n=4 versus 0.0096±0.0013, n=4; P=0.03) in
megakaryocytes derived from PMF CD34+ cultures as
compared to control IgG-treated cells (Figure 5C), suggest-
ing the possible role of CD9 in the CXCL12/CXCR4-
mediated process of megakaryocyte migration. As ligation
of CD9 by Syb monoclonal antibody induced cell aggre-
gates,26 we further investigated the functional participation
of CD9 on PMF megakaryocyte migration in response to
CXCL12 by treating megakaryocytes with siRNA CD9.
We first verified that addition of siRNA CD9 down-regu-
lated the CD9 expression in megakaryocytes derived from
PMF CD34+ cells (D9 of differentiation) at both transcript
level (2.32±2.78 AU, n=6, versus 5.78±6.66 AU, n=6;
P=0.04; fold change = -2.49, in siRNA CD9 versus siRNA
control treated cells, respectively) and protein level (50%
reduction 72 h after lipofection) (Figure 5D). We further
demonstrated that a 2-fold reduction of CD9 expression
inhibited the CXCL12-dependent migration of PMF
megakaryocytes derived from CD34+ cells, as shown by a
strong reduction of the percentage of migrating cells after
siCD9 treatment as compared to siRNA control treated
cells (115.5±20.9%, n=3 and 474.7±169.7%, n=3; respec-
tively; P=0.03) (Figure 5D). Silencing CD9 also significant-
ly reduced the Tyr576/577 phosphorylation level of FAK,
the focal adhesion kinase participating in megakaryocyte
migration, as compared to siRNA control treated cells
(15.42±10.54 MFI, n=5 and 24.12±15.22 MFI, n=5; respec-
tively; P=0.04). 
Discussion 
PMF is a chronic myeloproliferative neoplasm with
numerous alterations of megakaryocytes,27 which are
reported to play key roles in the pathophysiological
process. Tetraspanin CD9, known to participate in normal
megakaryocytic differentiation,17 has been described to be
deregulated in myeloproliferative neoplasms and especial-
ly in PMF.18 In the present study, we analyzed the potential
contribution of CD9 to PMF dysmegakaryopoiesis. Our
results show that CD9 (i) is deregulated during PMF
megakaryopoiesis; (ii) participates in PMF dysmegakary-
opoiesis through modulation of megakaryocyte matura-
tion, apoptosis and Akt/MAPK signaling pathway balance;
and (iii) mediates altered megakaryocyte interactions with
MSC from the BM of patients as well as altered megakary-
ocyte migration in response to CXCL12 chemokine.
We found that the CD9 gene was highly expressed in
CD34+ cells from PMF patients. As described by
Guglielmelli et al., such a high CD9 gene expression
appears to be related to PMF patients since it allows their
discrimination from healthy subjects and from patients
with polycythemia vera and essential thrombo-
cythemia.18 Interestingly, however, we showed that the
mean level of CD9 membrane expression is heteroge-
neous on PMF CD34+ cells and is reduced during in vitro
megakaryocyte differentiation to be lower on platelets
from patients than on those from HD, suggesting a dereg-
ulation of CD9 during PMF megakaryopoieisis. PMF dys-
megakaryopoieis is characterized by a defect of
PMF CD9-mediated megakaryocyte-stroma interactions
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Figure 5. CD9 mediates PMF megakaryocyte migration in response to CXCL12. (A) Expression of CXCR4 on CD41+ PMF megakaryocytes (Mk)
derived from PMF circulating CD34+ cells (D8-10 of culture) by flow cytometry and microscopy as compared to Mk derived from healthy donors
(unmobilized peripheral blood or bone marrow). (B) CD9 and CXCR4 coexpression on CD41low and CD41high PMF cells. (C) Effect of surface CD9
ligation by anti-CD9 monoclonal antiboby (mAb) (clone-SYB; 10 μg/mL)  on CXCR4 and CXCL12 transcript expression normalized to RPL38 by
QRT-PCR in Mk derived from PMF circulating CD34+ cells (D8-10 of culture). (D) Effect of silencing CD9 using siRNA CD9 (1 μg/106 cells) in Mk
derived from PMF circulating CD34+ cells (D8-10 of culture) on the CD9 transcript and protein expression levels analyzed by QRT-PCR (at 48
h) and by flow cytometry (at 72 h), respectively, and on the percentage of migrating PMF Mk in a Boyden chamber in response to CXCL12 (100
ng/mL) as compared to passive diffusion and on the phospho-FAK (Tyr 576/577) expression level (MFI).
D
C
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megakaryocyte maturation and apoptosis; cell surface
CD9 engagement by antibody ligation restored the in vitro
PMF megakaryocyte maturation and the apoptotic
process known be involved in megakaryocyte differentia-
tion.28 As reported for cancer cells,29 targeting CD9
restores apoptosis in PMF megakaryocytes and is accom-
panied by a normalization of the anti-apoptotic Bcl-xL
protein expression abnormally over-expressed in PMF
megakaryocytes.12 Ligation of CD9 on PMF megakaryo -
cytes also induces increased phosphorylation of JNK and
p38 MAPK associated with up-regulation of downstream
AP1 as well as with a reduction of Akt/GSK3β phospho-
rylation, two signaling pathways the balance of which is
reported to drive megakaryopoiesis.30 The expression of
c-myb, which also participates in megakaryopoiesis,31,32 is
decreased during megakaryocyte differentiation33 and is
regulated by GSK3β34 and p38/JNK.35 In PMF, the
increased c-myb expression observed in megakaryocyte
derived from CD34+ cells is therefore consistent with
reduced megakaryocyte maturation. Consequently, the
reduction of c-myb expression after CD9 ligation is com-
patible with its participation in PMF dysmegakary-
opoiesis through CD9 deregulation. 
PMF is characterized by the egress of CD34+ progenitors
and of micro-megakaryocytes from BM into peripheral
blood.1,36,37 By participating in the tetraspanin network,
CD9 can interact with molecules within rich lipid micro-
domains where the G protein-coupled receptors are regu-
lated.13 As an example, CD9 is reported to participate in
CXCL12-dependent CD34+ cell migration through modu-
lation of CXCR4 receptor expression.21 As evidenced by
bioinformatics prediction (Online Supplementary Figure S4),
myb regulatory sites are present in the promoter regions
of CXCL12 and CXCR4 genes, confirming that they are
both target genes of c-myb.38,39 In PMF, our results showing
that CD9 regulates CXCR4 and CXCL12 transcriptional
expression (Figure 5) and that this process is reversed by
silencing c-myb (data not shown), suggest a link between
CD9, the CXCL12/CXCR4 axis and c-myb in the deregu-
lated process of megakaryocyte migration. Thus, the
reduced CD9 expression during PMF megakaryopoieisis
may render megakaryocytes less sensitive to the CXCL12
chemotactic gradient present in the BM, contributing to
their mobilization. This hypothesis is in agreement with
the presence of micro-megakaryocytes in the peripheral
blood of PMF patients36 and with the role of reduced
CXCR4 expression in the increased PMF CD34+ cell
migration.9
In patients with myeloproliferative neoplasms, while
hematopoietic cells may have acquired similar mutations
such as JAK2V617F, MPL or CALR,7,40,41 alterations in
megakaryopoiesis differ according to the disease pheno-
type,42 suggesting that other factors, such as environmen-
tal ones, likely participate in the dysmegakaryopoiesis. In
PMF, the BM microenvironment is impaired and splenic
stromal cells are reported to exhibit altered differentiation
and functional characteristics.43 Our present data, show-
ing altered expression of CD9 on hematopoietic and stro-
mal cells from PMF patients as well as modulated expres-
sion on osteoblasts in advanced stages of the disease,19
suggest that CD9 and the tetraspanin web participate in
the altered interplay between hematopoietic and stromal
cells in patients. The reduced adhesion of megakaryocyte
to PMF-MSC associated with increased survival and pro-
liferation in co-cultures with stroma, which was corrected
after cell surface CD9 ligation, strengthens our hypothe-
sis. 
In conclusion, while the underlying mechanism for
alterations in CD9 expression in PMF is still unknown, this
study indicates that CD9 plays a role in PMF dys-
megakaryopoiesis and affects interactions between
megakaryocytes and BM stromal cells. Our results
strengthen the “bad seed in bad soil” hypothesis that we
have proposed in which alterations of the interplays
between hematopoietic and stromal cells participate in the
pathogenesis of the disease.1 Taking into account the role
of megakaryocytes and stromal cells in the pathogenesis
of PMF, they are of importance with regards to the recent
development of new therapeutic strategies. Indeed, by
regulating the apoptotic process, targeting CD9 may
improve the dysmegakaryopoiesis that characterizes PMF,
as demonstrated in human cancer cells.44 In the same way,
the role of the Akt pathway driven by CD9 in PMF
megakaryocytes is consistent with the findings of a recent
study that established Akt as a rational therapeutic target
for the treatment of patients with myeloproliferative neo-
plasms.45 In brief, our results indicate original therapeutic
avenues targeting hematopoietic cell-stroma interactions
in PMF.  
Acknowledgments
The authors are indebted to Prof Y Masse, Dr. C Blondeau
and Dr. A Touma (Hôpital Intercommunal, Aulnay-Sous-Bois,
France), to Prof. JV Malfuson (HIA Percy, Clamart, France), to
Ms Chantal Tisseuil, IDE Recherche Clinique (CHU Dupytren,
Limoges, France) and to Ms Corinne Grafl from the Department
of Internal Medicine I, Division of Hematology and
Hemostaseology (Medical University of Vienna, Austria) for sup-
plying samples from heathy donors and patients.
Funding 
This work was supported by grants from: the Association
"Vaincre le Cancer-Nouvelles Recherches Biomédicales",
Convention de Recherche INCa n. PL054 and n. R06031LP;
the Association pour la Recherche contre le Cancer (ARC, 9806),
“Laurette Fugain” Association (ALF/n. 06-06, project #
R06067LL), the “Contrat d’Interface” with Paul Brousse
Hospital, the "Groupement d'Intérêt Scientifique (GIS)-Institut
des Maladies Rares 03/GIS/PB/SJ/n. 35, the European Union-
EUMNET Project (QLRT-2001-01123), INCa (PL054 and
2007-1-PL5-Inserm 11-1), and the "Ligue Contre le Cancer"
(Equipe labellisée “LA LIGUE 2010”). The work in Florence
was supported by a special grant from Associazione Italiana per
la Ricerca sul Cancro-“AIRC 5 per Mille”- to AGIMM, “AIRC-
Gruppo Italiano Malattie Mieloproliferative” (#1005).
Authorship and Disclosures
Information on authorship, contributions, and financial & other
disclosures was provided by the authors and is available with the
online version of this article at www.haematologica.org.
C. Desterke et al.
766 haematologica | 2015; 100(6)
PMF CD9-mediated megakaryocyte-stroma interactions
haematologica | 2015; 100(6) 767
References
1. Lataillade JJ, Pierre-Louis O, Hasselbalch
HC, et al. Does primary myelofibrosis
involve a defective stem cell niche? From
concept to evidence. Blood. 2008;112(8):
3026-3035.
2. James C, Ugo V, Le Couedic JP, Staerk J, et al.
A unique clonal JAK2 mutation leading to
constitutive signalling causes polycythaemia
vera. Nature. 2005;434(7037):1144-1148.
3. Pardanani AD, Levine RL, Lasho T, et al.
MPL515 mutations in myeloproliferative
and other myeloid disorders: a study of 1182
patients. Blood. 2006;108(10):3472-3476.
4. Stegelmann F, Bullinger L, Schlenk RF, et al.
DNMT3A mutations in myeloproliferative
neoplasms. Leukemia. 2011;25(7):1217-
1219.
5. Abdel-Wahab O, Pardanani A, Patel J, et al.
Concomitant analysis of EZH2 and ASXL1
mutations in myelofibrosis, chronic
myelomonocytic leukemia and blast-phase
myeloproliferative neoplasms. Leukemia.
2011;25(7):1200-1202.
6. Lasho TL, Finke CM, Hanson CA, et al.
SF3B1 mutations in primary myelofibrosis:
clinical, histopathology and genetic corre-
lates among 155 patients. Leukemia.
2012;26(5):1135-1137.
7. Nangalia J, Massie CE, Baxter EJ, et al.
Somatic CALR mutations in myeloprolifera-
tive neoplasms with nonmutated JAK2. N
Eng J Med. 2013;369(25):2391-2405.
8. Vannucchi AM, Lasho TL, Guglielmelli P, et
al. Mutations and prognosis in primary
myelofibrosis. Leukemia. 2013;27(9):1861-
1869.
9. Bogani C, Ponziani V, Guglielmelli P, et al.
Hypermethylation of CXCR4 promoter in
CD34+ cells from patients with primary
myelofibrosis. Stem Cells. 2008;26(8):1920-
1930.
10. Florena AM, Tripodo C, Di Bernardo A, et
al. Different immunophenotypical apoptotic
profiles characterise megakaryocytes of
essential thrombocythaemia and primary
myelofibrosis. J Clin Pathol. 2009;62(4):331-
338.
11. Theophile K, Hussein K, Kreipe H, Bock O.
Expression profiling of apoptosis-related
genes in megakaryocytes: BNIP3 is down-
regulated in primary myelofibrosis. Exp
Hematol. 2008;36(12):1728-1738.
12. Ciurea SO, Merchant D, Mahmud N, et al.
Pivotal contributions of megakaryocytes to
the biology of idiopathic myelofibrosis.
Blood. 2007;110(3):986-993.
13. Charrin S, le Naour F, Silvie O, Milhiet PE,
Boucheix C, Rubinstein E. Lateral organiza-
tion of membrane proteins: tetraspanins
spin their web. Biochem J. 2009;420(2):133-
154.
14. Boucheix C, Perrot JY, Mirshahi M, et al. A
new set of monoclonal antibodies against
acute lymphoblastic leukemia. Leuk Res.
1985;9(5):597-604.
15. Boucheix C, Benoit P, Frachet P, et al.
Molecular cloning of the CD9 antigen. A
new family of cell surface proteins. J Biol
Chem. 1991;266(1):117-122.
16. Le Naour F, Francastel C, Prenant M, Lantz
O, Boucheix C, Rubinstein E. Upregulation
of CD9 expression during TPA treatment of
K562 cells. Leukemia. 1997;11(8):1290-1297.
17. Clay D, Rubinstein E, Mishal Z, et al. CD9
and megakaryocyte differentiation. Blood.
2001;97(7):1982-1989.
18. Guglielmelli P, Zini R, Bogani C, et al.
Molecular profiling of CD34+ cells in idio-
pathic myelofibrosis identifies a set of dis-
ease-associated genes and reveals the clinical
significance of Wilms' tumor gene 1 (WT1).
Stem Cells. 2007;25(1):165-173.
19. Bock O, Muth M, Theophile K, et al.
Identification of new target molecules PTK2,
TGFBR2 and CD9 overexpressed during
advanced bone marrow remodelling in pri-
mary myelofibrosis. Br J Haematol.
2009;146(5):510-520.
20. Rubinstein E, Le Naour F, Lagaudriere-
Gesbert C, Billard M, Conjeaud H, Boucheix
C. CD9, CD63, CD81, and CD82 are com-
ponents of a surface tetraspan network con-
nected to HLA-DR and VLA integrins. Eur J
Immunol. 1996;26(11):2657-2665.
21. Leung KT, Chan KY, Ng PC, Lau TK, Chiu
WM, Tsang KS, et al. The tetraspanin CD9
regulates migration, adhesion, and homing
of human cord blood CD34+ hematopoietic
stem and progenitor cells. Blood.
2011;117(6):1840-1850.
22. Desterke C, Bilhou-Nabera C, Guerton B, et
al. FLT3-mediated p38-MAPK activation
participates in the control of megakary-
opoiesis in primary myelofibrosis. Cancer
Res. 2011;71(8):2901-2915.
23. Pfaffl MW. A new mathematical model for
relative quantification in real-time RT-PCR.
Nucleic Acids Res. 2001;29(9):e45.
24. Vannucchi AM, Pancrazzi A, Guglielmelli P,
et al. Abnormalities of GATA-1 in
megakaryocytes from patients with idio-
pathic myelofibrosis. Am J Pathol.
2005;167(3):849-858.
25. Cheng L, Qasba P, Vanguri P, Thiede MA.
Human mesenchymal stem cells support
megakaryocyte and pro-platelet formation
from CD34(+) hematopoietic progenitor
cells. J Cell Physiol. 2000;184(1):58-69.
26. Lagaudriere-Gesbert C, Le Naour F, Lebel-
Binay S, et al. Functional analysis of four
tetraspans, CD9, CD53, CD81, and CD82,
suggests a common role in costimulation,
cell adhesion, and migration: only CD9
upregulates HB-EGF activity. Cell Immunol.
1997;182(2):105-112.
27. Thiele J, Kvasnicka HM, Zankovich R, Diehl
V. Clinical and morphological criteria for the
diagnosis of prefibrotic idiopathic (primary)
myelofibrosis. Ann Hematol. 2001;80(3):
160-165.
28. De Botton S, Sabri S, Daugas E, et al. Platelet
formation is the consequence of caspase
activation within megakaryocytes. Blood.
2002;100(4):1310-1317.
29. Nakamoto T, Murayama Y, Oritani K, et al.
A novel therapeutic strategy with anti-CD9
antibody in gastric cancers. J Gastroenterol.
2009;44(9):889-896.
30. Guerriero R, Parolini I, Testa U, et al.
Inhibition of TPO-induced MEK or mTOR
activity induces opposite effects on the
ploidy of human differentiating megakary-
ocytes. J Cell Sci. 2006;119(Pt 4):744-752.
31. Ono M, Matsubara Y, Shibano T, Ikeda Y,
Murata M. GSK-3beta negatively regulates
megakaryocyte differentiation and platelet
production from primary human bone mar-
row cells in vitro. Platelets. 2011;22(3):196-
203.
32. Hilton DJ, Kile BT, Alexander WS.
Mutational inhibition of c-Myb or p300
ameliorates treatment-induced thrombocy-
topenia. Blood. 2009;113(22):5599-5604.
33. Barroga CF, Pham H, Kaushansky K.
Thrombopoietin regulates c-Myb expres-
sion by modulating micro RNA 150 expres-
sion. Exp Hematol. 2008;36(12):1585-1592.
34. Kitagawa K, Kotake Y, Hiramatsu Y, et al.
GSK3 regulates the expressions of human
and mouse c-Myb via different mechanisms.
Cell Div. 2010;5:27.
35. Nicolaides NC, Correa I, Casadevall C,
Travali S, Soprano KJ, Calabretta B. The Jun
family members, c-Jun and JunD, transacti-
vate the human c-myb promoter via an Ap1-
like element. J Biol Chem. 1992;267
(27):19665-19672.
36. Castro-Malaspina H. Pathogenesis of
myelofibrosis: role of ineffective megakary-
opoiesis and megakaryocyte components.
Prog Clin Biol Res. 1984;154:427-454.
37. Barosi G, Grossi A, Comotti B, Musto P,
Gamba G, Marchetti M. Safety and efficacy
of thalidomide in patients with myelofibro-
sis with myeloid metaplasia. Br J Haematol.
2001;114(1):78-83.
38. Quintana AM, Liu F, O'Rourke JP, Ness SA.
Identification and regulation of c-Myb target
genes in MCF-7 cells. BMC Cancer. 2011;
11:30.
39. Chen L, Xu S, Zeng X, et al. c-myb activates
CXCL12 transcription in T47D and MCF7
breast cancer cells. Acta Biochim Biophys
Sin. 2010;42(1):1-7.
40. Tefferi A. Novel mutations and their func-
tional and clinical relevance in myeloprolif-
erative neoplasms: JAK2, MPL, TET2,
ASXL1, CBL, IDH and IKZF1. Leukemia.
2010;24(6):1128-1138.
41. Tefferi A, Thiele J, Vannucchi AM, Barbui T.
An overview on CALR and CSF3R muta-
tions and a proposal for revision of WHO
diagnostic criteria for myeloproliferative
neoplasms. Leukemia. 2014;28(7):1407-
1413.
42. Balduini A, Badalucco S, Pugliano MT, et al.
In vitro megakaryocyte differentiation and
proplatelet formation in ph-negative classi-
cal myeloproliferative neoplasms: distinct
patterns in the different clinical phenotypes.
PloS one. 2011;6(6):e21015.
43. Brouty-Boye D, Briard D, Azzarone B, et al.
Effects of human fibroblasts from
myelometaplasic and non-myelometaplasic
hematopoietic tissues on CD34+ stem cells.
Int J Cancer. 2001;92(4):484-488.
44. Murayama Y, Miyagawa J, Oritani K, et al.
CD9-mediated activation of the p46 Shc iso-
form leads to apoptosis in cancer cells. J Cell
Sci. 2004;117(Pt 15):3379-3388.
45. Khan I, Huang Z, Wen Q, et al. AKT is a
therapeutic target in myeloproliferative neo-
plasms. Leukemia. 2013;27(9):1882-1890.
